Navigation Links
Study: Low bone density medications may have protective effect on endometrial cancer
Date:3/21/2012

DETROIT: Low bone density medications, such as Fosamax, Boniva and Actonel, may have a protective effect for endometrial cancer, according to a study at Henry Ford Hospital.

Endometrial cancer affects more than 45,000 women a year in the U.S., usually in their 60s, although it can occur before 40. A type of uterine cancer, it's the most commonly diagnosed gynecologic cancer, and there is no known preventive medication for women at high risk of developing it.

"The results of the study suggest that use of low bone density medications may have a protective effect on endometrial cancer, or that women who take them get a less-aggressive cancer," says Sharon Hensley Alford, Ph.D, lead author of the study, and a researcher in Public Health Services at Henry Ford Hospital.

The classification for these medications is bisphosphonates.

In the fifth year of the ongoing trial, all participants were asked to complete a supplemental questionnaire, which included questions about their use of medications that treat thinning bones.

A total of 29,254 women were included in the analysis, for which 115 endometrial cancers have been diagnosed since the completion of the questionnaires.

The rate of endometrial cancer among women who had taken bisphosphonates was approximately half that of women who had never taken the medication (9.6 vs. 18.7 per 10,000 person years). The effect was more significant with less-aggressive cancers.

Dr. Alford is presenting the study March 24 at the Society of Gynecologic Oncology's 2012 Annual Meeting on Women's Cancer in Austin, Texas.

Henry Ford researchers used data from the National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian Screening Trial, which collected data on all cancer outcomes for trial participants.

At the time the women were recruited for the trial, they ranged from 55 to 70 years old.

Women with missing information on bone medication use were excluded. Only women who had not had a hysterectomy were included in the analysis.

Women without a cancer diagnosis at the time of the questionnaire were separated into groups: those who reported current or past use of a bisphosphonate, defined as "ever used", and women who had never used such medications.

This study alone would not change clinical practice, and more study is necessary, according to Dr. Alford.

"This was a retrospective study, with self-reported data," says Dr. Alford. "A clinical trial, with closely monitored data, needs to be done for definitive results."


'/>"/>

Contact: Sally Ann Brown
sbrown2@hfhs.org
313-282-9058
Henry Ford Health System
Source:Eurekalert

Related medicine news :

1. Study: Choice between stroke-prevention procedures influenced by patient age
2. UNC study: Obese 3-year-olds show early warning signs for future heart disease
3. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
4. Henry Ford Hospital study: Shoulder function not fully restored after surgery
5. Study: Federal funds support health depts., but leadership is key
6. Study: Kidney disease a big risk for younger, low-income minorities
7. Study: Mechanomyography to be accurate in detecting nerves during minimally invasive spine surgery
8. Study: Low Levels of Vitamin D Linked to Higher Rates of Asthma in African American Kids
9. Study: Child health may suffer in strong economy
10. Study: Social influence playing role in surging autism diagnoses
11. Children's Rights Group Agrees with New Study: Infant Circumcision Causes 100 Deaths Each Year in US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... In the ... forward. They’ll groom themselves to perfection, go out of their way to be romantic, ... – just take a look at any online dating profile. , A recent ...
(Date:2/12/2016)... , ... February 12, 2016 , ... According to an ... are beginning to account for a significant portion of hernia repairs throughout the United ... the Beverly Hills Hernia Center notes that this trend has not only been expected, ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & ... purpose of these scholarships is to encourage applicants to pursue a degree in their ... these two parishes. , “We have available jobs in St. Landry and Evangeline ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February ...
(Date:2/12/2016)... ... 12, 2016 , ... Fixed Dose Combination Drug Development: , ... http://www.fdanews.com/fixeddosecombination , Fixed dose combination products are a ... from all stakeholders in the development of new chemical entities. , However, the ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... and Company (NYSE: LLY ) today announced that the ... patent would not presently be infringed by Actavis marketing pemetrexed ... Italy and Spain ... --> --> In ... Lilly,s patent would be indirectly infringed by Actavis marketing certain ...
(Date:2/12/2016)... North Carolina , 12 februari 2016 ... Inc. (AAI/CML), een toonaangevende leverancier van productie ... en biotechnologische industrieën, kondigt vandaag een uitbreiding ... mogelijkheden op haar locatie in ... vraag heeft geleid tot meerdere recente investeringen. ...
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
Breaking Medicine Technology: